Topiramate
Product Images NDC 70934-450

4 FDA label images from Denton Pharma, Inc. Dba Northwind Pharmaceuticals · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 70934-450). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Denton Pharma, Inc. Dba Northwind Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Topi (022dc727 C077 4611 8a3d 967ee99f9828 01)

Topi (022dc727 C077 4611 8a3d 967ee99f9828 01)
Chemical structure of the active ingredient topiramate, showing its molecular arrangement with various functional groups and stereochemistry as depicted in the diagram.*
FDA Label Image

Topi (022dc727 C077 4611 8a3d 967ee99f9828 02)

Topi (022dc727 C077 4611 8a3d 967ee99f9828 02)
A Kaplan-Meier plot showing cumulative rates for time to first seizure over 500 days comparing Topiramate 50 mg/day (solid line, N=234) with Topiramate 400 mg/day (dotted line, N=236). The x-axis represents time in days and the y-axis cumulative rates. A p-value of 0.0002 is noted.*
FDA Label Image

Figure 2: Reduction In 4-week Migraine Headache Frequency (studies 10 And 11 For Adults And Adolescents) (022dc727 C077 4611 8a3d 967ee99f9828 03)

Figure 2: Reduction In 4-week Migraine Headache Frequency			(studies 10 And 11 For Adults And Adolescents) (022dc727 C077 4611 8a3d 967ee99f9828 03)
A bar graph comparing the change from baseline to double-blind phase in average weekly migraine days per 28-day period across four groups: Placebo, Topamax 50 mg/day, Topamax 100 mg/day, and Topamax 200 mg/day. Two studies (Study 10 and Study 11) are represented, showing greater reductions in migraine days with increasing Topamax dosage compared to placebo. Statistical significance is indicated for higher doses.*
FDA Label Image

Label (70934 450 30 Master Bottle Label Approval Rev A 10 19)

Label (70934 450 30 Master Bottle Label Approval   Rev A 10 19)
Topiramate Tablets, USP 50 mg by Denton Pharma, Inc. dba Northwind Pharmaceuticals. The label indicates a package containing 30 tablets with prescription-only status. Storage instructions specify protecting from moisture, storing in the original container, and temperature control (20°-25°C). The label includes NDC 70934-450-30 and batch and expiration date placeholders.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.